Neoliberaler Kapitalismus gegen Soziale Marktwirtschaft und Wohlfahrtsstaat

"Die Ausdifferenzierung von Wirtschaft und politischen Institutionen hat sich durch die Entwicklung der internationalen Kapitalmärkte verstärkt. Gleichzeitig geschieht eine Integration durch Globalisierung. Die Verselbständigung der Märkte und der Versuch politische Beschlüsse zu dominieren bedroht die Demokratie. Im westlichen Kapitalismus stehen sich heute die neoliberale Gestaltung und die soziale Marktwirtschaft gegenüber. Ihre charakteristische Merkmale werden erstens analysiert. Die neoliberale Marktwirtschaft wird eher als extrem individualistisch gesehen. Die soziale Marktwirtschaft setzt durch ihre Betonung der Wertrationalität Grenzen für die instrumentelle Vernunft. Zweitens werden die ideologischen Hintergründe der Theorien, auf die sich die Vertreter der beiden Varianten stützen, analysiert. In diesem ideologiekritischen Unternehmen werden fünf Dimensionen von methodologischer und ontologischer Art hervorgehoben: 1. methodologischer Individualismus kontra Holismus; 2. politischer Individualismus kontra Kommunitarianismus; 3. strategisches soziales Handeln kontra kommunikatives; 4. zweckrationelles Verhalten kontra wertrationelles; 5. utilitaristische Moral kontra Gerechtigkeit und Gleichheit als moralische Ziele. Diese fünf Dimensionen bilden ein Gerüst für die Theoriebildung, die Weber und Marx mit der heutigen Entwicklung verbindet." (Autorenreferat

The Role of Certainty in a Two-Person Volunteer’s Dilemma

In the standard volunteer’s dilemma (VoD), a single prosocial act (i.e., volunteering) yields the optimal overall outcome. Whereas the volunteer’s outcome is certain, the defector’s outcome depends on what others do. This research addressed the confounding of prosocial responses with uncertainty avoidance in the standard VoD. In Experiment 1, participants (N = 102) considered 18 hypothetical one-shot two-person VoD scenarios with certain, risky, and uncertain outcomes when volunteering. In Experiment 2, participants (N = 496) considered three hypothetical one-shot two-person VoD scenarios; a certain VoD and two uncertain VoDs of which one had a lower expected collective outcome of volunteering than the certain VoD and the other a higher one. Results suggest that volunteering does not reflect a desire to avoid uncertainty but to maximize expected collective outcomes, reinforcing the assumption that the high volunteering rates we see in a standard VoD are due to social/moral preferences and social projection

Polar and Magnetic Mn2FeMO6 (M = Nb, Ta) with LiNbO3-type Structure - High Pressure Synthesis

Polar oxides are of much interest in materials science and engineering. Their symmetry-dependent properties such as ferroelectricity/multiferroics, piezoelectricity, pyroelectricity, and second-order harmonic generation (SHG) effect are important for technological applications. However, polar crystal design and synthesis is challenging, because multiple effects, such as steric or dipole-dipole interactions, typically combine to form non-polar structures; so the number of known polar materials, especially polar magnetoelectric materials, is still severely restricted. Therefore, it is necessary for the material science community to develop new strategies to create these materials

Building Tomograph – From Remote Sensing Data of Existing Buildings to Building Energy Simulation Input

Existing buildings often have low energy efficiency standards. For the preparation of retrofits, reliable high-quality data about the status quo is required. However, state-of-the-art analysis methods mainly rely on on-site inspections by experts and hence tend to be cost-intensive. In addition, some of the necessary devices need to be installed inside the buildings. As a consequence, owners hesitate to obtain sufficient information about potential refurbishment measures for their houses and underestimate possible savings. Remote sensing measurement technologies have the potential to provide an easy-to-use and automatable way to energetically analyze existing buildings objectively. To prepare an energetic simulation of the status quo and of possible retrofit scenarios, remote sensing data from different data sources have to be merged and combined with additional knowledge about the building. This contribution presents the current state of a project on the development of new and the optimization of conventional data acquisition methods for the energetic analysis of existing buildings solely based on contactless measurements, general information about the building, and data that residents can obtain with little effort. For the example of a single-family house in Morschenich, Germany, geometrical, semantical, and physical information are derived from photogrammetry and quantitative infrared measurements. Both are performed with the help of unmanned aerial vehicles (UAVs) and are compared to conventional methods for energy efficiency analysis regarding accuracy of and necessary effort for input data for building energy simulation. The concept of an object-oriented building model for measurement data processing is presented. Furthermore, an outlook is given on the project involving advanced remote sensing techniques such as ultrasound and microwave radar application for the measurement of additional energetic building parameters

The cross-sectional GRAS sample: A comprehensive phenotypical data collection of schizophrenic patients

<p>Abstract</p> <p>Background</p> <p>Schizophrenia is the collective term for an exclusively clinically diagnosed, heterogeneous group of mental disorders with still obscure biological roots. Based on the assumption that valuable information about relevant genetic and environmental disease mechanisms can be obtained by association studies on patient cohorts of ≥ 1000 patients, if performed on detailed clinical datasets and quantifiable biological readouts, we generated a new schizophrenia data base, the GRAS (Göttingen Research Association for Schizophrenia) data collection. GRAS is the necessary ground to study genetic causes of the schizophrenic phenotype in a 'phenotype-based genetic association study' (PGAS). This approach is different from and complementary to the genome-wide association studies (GWAS) on schizophrenia.</p> <p>Methods</p> <p>For this purpose, 1085 patients were recruited between 2005 and 2010 by an invariable team of traveling investigators in a cross-sectional field study that comprised 23 German psychiatric hospitals. Additionally, chart records and discharge letters of all patients were collected.</p> <p>Results</p> <p>The corresponding dataset extracted and presented in form of an overview here, comprises biographic information, disease history, medication including side effects, and results of comprehensive cross-sectional psychopathological, neuropsychological, and neurological examinations. With >3000 data points per schizophrenic subject, this data base of living patients, who are also accessible for follow-up studies, provides a wide-ranging and standardized phenotype characterization of as yet unprecedented detail.</p> <p>Conclusions</p> <p>The GRAS data base will serve as prerequisite for PGAS, a novel approach to better understanding 'the schizophrenias' through exploring the contribution of genetic variation to the schizophrenic phenotypes.</p

The OASIS Mission

The Orbiting Astrophysical Observatory in Space (OASIS) is a mission to investigate Galactic Cosmic Rays (GCRs), a major feature of our galaxy. OASIS will use measurements of GCRs to determine the cosmic ray source, where they are accelerated, to investigate local accelerators and to learn what they can tell us about the interstellar medium and the processes that occur in it. OASIS will determine the astrophysical sources of both the material and acceleration of GCRs by measuring the abundances of the rare actinide nuclei and make direct measurements of the spectrum and anisotropy of electrons at energies up to approx.10 TeV, well beyond the range of the Fermi and AMS missions. OASIS has two instruments. The Energetic Trans-Iron Composition Experiment (ENTICE) instrument measures elemental composition. It resolves individual elements with atomic number (Z) from 10 to 130 and has a collecting power of 60m2.str.yrs, >20 times larger than previous instruments, and with improved resolution. The sample of 10(exp 10) GCRs collected by ENTICE will include .100 well-resolved actinides. The High Energy Particle Calorimeter Telescope (HEPCaT) is an ionization calorimeter that will extend the electron spectrum into the TeV region for the first time. It has 7.5 sq m.str.yrs of collecting power. This talk will describe the scientific objectives of the OASIS mission and its discovery potential. The mission and its two instruments which have been designed to accomplish this investigation will also be described

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p&lt;0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (&lt;1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (&lt;1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline